

KALVISTA PHARMACEUTICALS, INC.

One Kendall Square,
Bld 200, Ste 2203
Cambridge, MA 02139

April 26, 2017

United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549

Attention: Suzanne Hayes
Assistant Director
Office of Healthcare and Insurance

Re: KalVista Pharmaceuticals, Inc.
Registration Statement on Form S-3
Filed March 29, 2017, as amended
File No. 333-217009

Via EDGAR—Acceleration Request

Requested Date: April 28, 2017

Requested Time: 4:00 p.m. Eastern Time

Ladies and Gentlemen:

KalVista Pharmaceuticals, Inc. (the “**Registrant**”) hereby requests that the Securities and Exchange Commission (the “**Commission**”) take appropriate action to make the above-captioned Registration Statement on Form S-3 effective at the “Requested Date” and “Requested Time” set forth above or as soon thereafter as practicable.

The Registrant hereby authorizes Robert A. Freedman or Effie Toshav, both of whom are attorneys with the Registrant’s outside legal counsel, Fenwick & West LLP, to orally modify or withdraw this request for acceleration.

Sincerely,

KALVISTA PHARMACEUTICALS, INC.

By: /s/ Benjamin L. Palleiko
Benjamin L. Palleiko
Chief Financial Officer

cc: Thomas Andrew Crockett, Chief Executive Officer
KalVista Pharmaceuticals, Inc.

Robert A. Freedman, Esq.
Effie Toshav, Esq.
Fenwick & West LLP